Pharma helps foot bill for US$750,000 drug, but seeks personal medical info in return
Derwood,United States
KRISTEN Lasko cried tears of relief in late December when she read online that an experimental drug that could help her 3 1/2-year-old son, Max, had finally been approved. Ms Lasko and her husband, Jonathan, quickly pivoted to getting their cheerful, blonde boy access to the only approved medicine for a devastating, muscle-wasting disease. The drug, Spinraza, would carry a staggering price: US$750,000 for the first year.
Max's rare, life-threatening disease, spinal muscular atrophy, confined him to a wheelchair and robbed him of muscles he needs to smile and swallow. Spinraza, developed by the Massachusetts biotech company Biogen, had helped other children with the disease sit, stand or even walk.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
Billionaire Geiger is said to near US$7 billion L’Occitane buyout
HCA beats first-quarter profit estimates on higher patient admissions